Quark Pharmaceuticals Company Description
Quarks may be the basic building blocks of matter, but it's a fundamental unit of biology -- genes -- that Quark Pharmaceuticals is interested in. The drug development company is using cutting-edge RNA interference technology to develop siRNAs, or drugs that inhibit targeted genes from producing proteins associated with certain diseases. Its lead product RTP801i-14, which it has licensed to Pfizer, aims to treat wet age-related macular degeneration (a cause of blindness in the elderly). Quark Pharmaceuticals is developing other candidates for acute renal failure and hearing loss, and it has licensed BT16, a potential treatment for dyslipidemia, to Japanese drug firm Sanwa for development in Far East markets.
View the Comprehensive Company Description for Quark Pharmaceuticals
The Company Description provides a historical perspective of Quark Pharmaceuticals's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Quark Pharmaceuticals's evolution in the marketplace.
